Connect with us

Press Release

Vantage Vascular Selected for National RESORB Knee test Brooklyn NY and Fair Lawn NJ

Published

on

Vantage Vascular is one of just over 10 U.S. practices chosen to participate in the landmark RESORB clinical test for knee osteoarthritis pain.

Brooklyn, NY, United States, 10th Jul 2026 – Vantage Vascular, an outpatient vascular and interventional radiology practice serving patients across New York and New Jersey, has been selected as one of just over 10 leading U.S. clinical sites chosen to participate in the RESORB clinical test, a landmark national study evaluating a breakthrough, non-surgical treatment for knee osteoarthritis pain. 

Being named a RESORB test site is not automatic. NEXTBIOMEDICAL, the study sponsor, specifically sought out practices with the clinical expertise, imaging capabilities, and patient-first infrastructure to effectively conduct a pivotal FDA test. 

RESORB (Randomized Controlled Study Evaluating Genicular Artery Embolization Against Intra-Articular Corticosteroid Knee Injection for Osteoarthritic Knee Pain) is a pivotal, FDA-approved clinical test comparing genicular artery embolization (GAE) using an investigational device called Nexsphere F to a standard corticosteroid knee injection. The test is enrolling approximately 126 patients across more than 10 U.S. sites and is registered on ClinicalTrials.gov as NCT06872567.

Genicular artery embolization is a minimally invasive, outpatient procedure in which board-certified interventional radiologists use image guidance to deliver tiny particles into blood vessels feeding the inflamed tissues of the knee.

Nexsphere F is a novel, fast-resorbable microsphere technology. Unlike permanent embolic agents, Nexsphere F microspheres dissolve naturally within 2 to 6 hours after the procedure.

Term blockage of blood flow. The device has already received FDA Breakthrough Device Designation, CMS IDE Category B approval (meaning Medicare covers the procedure during the test), and CE-MDD certification in Europe, where it has been used in thousands of procedures with a strong safety record.

Why Being a Selected test Site Matters for Patients

Clinical test site selection for an FDA pivotal study is highly competitive. Sponsors identify practices based on physician expertise, procedural volume, imaging infrastructure, and the ability to safely manage research protocols. 

For patients, what this means in practice is significant: Vantage Vascular is offering access to a treatment not yet available anywhere outside of these select test sites in the United States. If you have knee osteoarthritis pain that has persisted despite medications and conservative care for at least two months, and you are not currently planning knee surgery or replacement, you may be eligible to receive this FDA-monitored, cutting-edge procedure at no cost through the test.

The test’s national Principal Investigator and Chief Medical Officer for NEXTBIOMEDICAL is Dr. Ziv J. Haskal, MD, Professor of Interventional Radiology at the University of Virginia. The clinical evidence behind Nexsphere F continues to grow: a published study in the Journal of Vascular and Interventional Radiology evaluating 155 patients treated with resorbable microspheres found a 67% average reduction in pain at 6 months, with no device-related serious adverse events.

Who May Be Eligible

The RESORB test is enrolling adults who:

• Have knee osteoarthritis pain that has not responded adequately to conservative treatments for at least 2 months

• Are not currently planning knee surgery or knee replacement

• Meet the study’s eligibility criteria as reviewed by Vantage Vascular’s clinical team

If enrolled, participants are randomly assigned to receive either GAE with Nexsphere F or a corticosteroid knee injection. Those initially assigned to the corticosteroid injection have the option to receive GAE after 180 days. The test runs approximately 12 to 18 months, and participation is always voluntary.

The test is FDA-IDE and IRB-approved (IRB approval at the protocol level: October 31, 2025). During the test, the procedure is covered under CMS IDE Category B, meaning Medicare-eligible patients may have coverage for test participation.

Schedule a Consultation at Vantage Vascular

If you or someone you know has been living with chronic knee pain, now is the time to explore whether you qualify. Vantage Vascular’s team will evaluate your history, imaging, and treatment background to determine eligibility and walk you through every step of the process with the same compassionate, patient-first care the practice is known for.

Enrollment is currently open at Vantage Vascular’s Brooklyn and New Jersey locations. Call or visit the practice online to schedule a consultation.

Brooklyn Flatlands Clinic: 2035 Ralph Ave, Suite B5, Brooklyn, NY 11234

Brooklyn Midwood Clinic: 603 Rugby Road, Suite 3, Brooklyn, NY 11230

New Jersey Fair Lawn Clinic: 15-01 Broadway, Suites 1–3, Fair Lawn, NJ 07410

NY: (718) 247-8794 | NJ: (201) 812-2929 | Monday–Friday: 8AM–6PM | vantagevascular.com

About Vantage Vascular

Vantage Vascular is an outpatient vascular and interventional radiology practice with locations in Brooklyn, New York and Fair Lawn, New Jersey. Led by Dr. Vishal K. Sinha, MD (Founder & President) and Dr. Christopher M. Harnain, MD, MBA, RPVI (Chief of Interventional Radiology & Founding Member), the practice’s Ivy League-educated, board-certified interventional radiologists deliver world-class, minimally invasive treatments for joint pain, vascular conditions, women’s health, and more — all in a comfortable outpatient setting, with no hospital stays or prolonged recovery. Vantage Vascular is dedicated to advancing patient care through innovation, clinical excellence, and a deep commitment to the communities of New York and New Jersey.

About the RESORB test

RESORB is a randomized, open-label, FDA-IDE and IRB-approved pivotal clinical test evaluating genicular artery embolization with Nexsphere F  against intra-articular corticosteroid knee injection for osteoarthritic knee pain. The study is registered on ClinicalTrials.gov as NCT06872567, with an estimated enrollment of 126 participants at more than 10 leading U.S. clinical sites. Nexsphere F has received FDA Breakthrough Device Designation, CMS IDE Category B approval, and CE-MDD certification in Europe.

Important Research Notice

Nexsphere F is an investigational device not yet approved or cleared by the FDA for commercial use in the United States. It is available only through the RESORB clinical test at authorized test sites. Participation is subject to eligibility criteria, informed consent, site availability, and investigator review. Individual results may vary. Medicare coverage under CMS IDE Category B applies to eligible participants during the test period; patients should confirm coverage with Vantage Vascular and their insurer.

Media Contact

Organization: Vantage Vascular

Contact Person: Vishal K. Sinha

Website: https://vantagevascular.com/

Email: Send Email

Contact Number: +17182478794

Address:2035 Ralph Ave Ste B

City: Brooklyn

State: NY

Country:United States

Release id:46614

The post Vantage Vascular Selected for National RESORB Knee test Brooklyn NY and Fair Lawn NJ appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Hola Prime’s Second Deloitte Review Confirms 99.9% One-Hour Payouts, Zero Denials Across $8.43M in Payouts

Published

on

New York, USA, November 5th, 2026, FinanceWire

12-month operational review of 2.3M trades and 139,000+ accounts confirms 99.9% of payout requests processed in under one hour with zero payout denials.

Hola Prime, a global proprietary trading firm, today announced the publication of its second independent operational review conducted by Deloitte. Expanding its commitment to industry accountability under its new “The Whole Truth” campaign, the 12-month evaluation provides an comprehensive, data-driven look into the firm’s trade execution, account journeys, and payout performance.

Unlike standard industry marketing claims, the review offers complete operational visibility by evaluating 6,315 payout transactions, 139,320 account records, and approximately 2.3 million trade records across three major trading platforms.

Key Findings from the 12-Month Independent Review:

  • Payout Processing Performance: 99.9% of payout requests were processed within one hour, backing Hola Prime’s signature 1-Hour Payout commitment. The average payout processing time across the reviewed transactions was 31 minutes.
  • Capital Distributed: $8.43 million was paid out to traders over the last 12-month period till 15th Oct’26, with more than 50% of funded traders receiving more than one (multiple payouts). 
  • Zero Payout Denials: No payout requests were denied during the 12-month assessment period, with 100% of the requests raised, resulting in successful payouts.
  • Zero Median Slippage: Trade execution quality across 2.3 million trade records revealed zero median slippage on cTrader across all 10 of Hola Prime’s most frequently traded instruments.
  • Unfiltered Performance Data: Evaluation pass rates ranged between 22.53% and 32.41% across account plans, reflecting the real traders’ outcomes rather than curated success stories.

“Every prop firm claims they pay their traders, we believe traders deserve proof over promises,” said Somesh Kapuria, CEO of Hola Prime. “That’s why we’ve opened 12 months of operational data to independent scrutiny for the second time. We are publishing the reviewed numbers by a reputed Big four Audit firm, that make us proud alongside the realistic metrics that usually get hidden behind marketing spin. Trust shouldn’t be requested; it must be demonstrated.”

Through The Whole Truth initiative, Hola Prime is challenging the broader proprietary trading sector to move away from unverified payout screenshots and adopt regular, third-party operational verification as standard practice.

The full Deloitte review is available to the public at www.holaprime.com.

About Hola Prime

Hola Prime is a global proprietary trading firm empowering skilled traders worldwide with funded accounts and direct access to significant capital across Forex, commodities, and indices. Built on its industry-first 1-Hour Payout model and a commitment to radical transparency, Hola Prime was named Global Most Transparent Prop Firm 2025 by Finance Magnates and Fastest Payout Prop Firm MEA 2026 by UF Awards. Backed by a 4.6 Trustpilot rating and an active global community under #WeAreTraders, Hola Prime is redefining industry expectations.

Contact

Manya Bhardwaj
HolaPrime
contactus@holaprime.com

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Interest in Indoor Playgrounds Jumps 44% in Philadelphia as November Arrives

Published

on

Searches for indoor playgrounds climb as soon as the cold arrives, a pattern Playspace by Kidology also sees with families at its two locations.

Philadelphia, Pennsylvania, United States, 5th Nov 2026 — Every year, Playspace by Kidology sees families head indoors as the cold arrives. While reviewing search trends as part of its seasonal marketing research, the team found that the same shift shows up clearly online. According to search data from Ahrefs, a search research platform, searches for “indoor playground philadelphia” run 37% above their yearly average in November and keep climbing through the season: 19% above average in December, 66% above in January and still 14% to 17% above in February and March. From April to September, the same searches fall 12% to 36% below average.

Interest in Indoor Playgrounds Jumps 44% in Philadelphia as November Arrives

Google Trends shows the same pattern over a longer period. Across the past five years in the Philadelphia area, interest in “indoor playground” has been about 44% higher in November than in October, and it has reached its highest point between December and February every winter.

The timing follows the weather. Average highs in Philadelphia drop from about 56°F in November to about 40°F in January, the coldest month of the year, with average lows in the mid-20s. The pattern is national too: searches for “indoor playground near me” average about 44,000 a month in the U.S. and reach their highest point in January, 27% above average.

“We see it every year at our own front door: as soon as the cold sets in, more families come in looking for somewhere warm where their little ones can climb, run and burn off energy,” said Luba Patlakh Kaplun, founder of Kidology. “When we looked at the search data, it showed the same thing, and it starts earlier than many people think. Winter is long in Philadelphia, and for parents of toddlers and young kids, an indoor playground is one of the easiest ways to keep active play in the week, whatever the weather.”

What the numbers mean for Philadelphia families

  1. Winter planning starts in November, not January. Local searches for indoor playgrounds are already 37% above average in November. Families who line up their cold-weather outings now have a plan before the January peak.
  2. Birthday party venues are booked early. Nationally, searches for kids’ birthday party venues run 49% above average in November and 58% above in January, so winter and spring party dates go quickly.
  3. Indoor play isn’t only a winter thing. There is a second, smaller rise in summer: searches for indoor activities for kids are 30% above average in July, when the heat keeps families inside.

About Playspace by Kidology

Playspace by Kidology is an indoor playground for children from birth to 12, with locations in Northeast Philadelphia and Southampton, Bucks County. Kids climb rock walls, go down slides and play in sensory-friendly spaces. The playground is also available for birthday party rentals and play gift cards are available for the holidays.

For more information, visit kidologyplayspaces.com

Media Contact

Organization: Playspace by Kidology

Contact Person: Luba Patlakh Kaplun

Website: https://kidologyplayspaces.com/

Email: Send Email

Contact Number: +12153304116

Address: 928 Jaymor Rd c150, Southampton, PA 18966

Address 2: 2800 Southampton Rd, Philadelphia, PA 19154

City: Philadelphia

State: Pennsylvania

Country: United States

Release id: 50488

View source version on King Newswire:
Interest in Indoor Playgrounds Jumps 44% in Philadelphia as November Arrives

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Maylene Showcases Its Best-Selling Research Peptides with UK-Wide Delivery

Published

on

Research-use catalogue combines prefilled formats, clear product specifications and supporting documentation, with free delivery across the United Kingdom.

United Kingdom, 5th Nov 2026 – Maylene is putting the spotlight on its best-selling research peptide range, giving laboratory buyers access to an online catalogue backed by UK dispatch, clearly displayed pricing and available product documentation.

Maylene Showcases Its Best-Selling Research Peptides with UK-Wide Delivery

The Maylene platform brings together research peptides, individual compound listings and educational resources in one place. Visitors can explore available products, compare labelled strengths and review format and pack information before placing an order.

With free UK-wide delivery, Maylene offers a convenient purchasing option for laboratory buyers who value accessible product information and straightforward ordering. Its catalogue includes individual compounds, blends and bundles, allowing customers to browse different options according to their research requirements.

Featured Compounds Across the Maylene Range

Maylene’s featured selection includes BPC-157, GHK-Cu, retatrutide and compound blends, giving laboratory buyers a range of research-use options to explore. Each listing clearly presents the product name, labelled content, format and price, making it easier to compare specifications and review available supporting documentation before ordering.

This presentation gives customers a practical basis for comparison. Rather than relying on a product name alone, visitors can review the stated strength, check the selected pack and examine any supporting records available for that product.

For buyers exploring multiple options, dedicated collections make it easier to navigate the catalogue and move between individual listings. Product bundles are also presented separately, helping visitors distinguish a single item from a combined purchase.

Prefilled Research Formats in One Collection

The Maylene peptide pen collection brings together prefilled single-compound and blend products. Listings identify labelled content and pack quantities so laboratory buyers can compare available formats with greater clarity.

The distinction between individual content and total pack content is particularly useful when reviewing multipacks. A pack containing two pens has a different specification from a single pen carrying the same combined total. Maylene’s product information allows visitors to check those details before purchasing.

Blend listings also provide composition information, giving buyers a way to review the individual compounds within a product rather than relying only on its combined labelled strength.

All products in the collection are supplied for laboratory and research purposes only.

Product Documentation Available for Review

Alongside its catalogue, Maylene provides access to published laboratory reports where available. Customers can review these records and check whether the documentation corresponds to the product and strength they intend to purchase.

Maylene explains that published reports relate to the samples tested. They do not verify every batch in stock, and report coverage is not available for every product. Buyers should therefore check the documentation relevant to their exact item and contact the team where further clarification is needed.

Making these distinctions visible gives customers a more useful basis for evaluating product information. Labelled specifications, published records and batch details each serve a different purpose and should be considered together.

Free UK Delivery and Direct Support

Maylene offers free delivery across the United Kingdom, with products dispatched from the UK and tracking information provided after dispatch. International shipping is also available, with delivery details presented on the website.

Customers can review ordering information before completing a purchase, including their selected product, pack quantity and total. For questions about available documentation, product specifications or the ordering process, Maylene provides direct support through its listed contact channels.

This combination of UK fulfilment and accessible support gives laboratory buyers a clear route from browsing the catalogue to resolving product-specific enquiries.

Research Resources Beyond the Catalogue

Maylene’s website also features educational guides and compound information, providing additional context for visitors exploring its range. These resources sit alongside the commercial catalogue, allowing buyers to review background information while checking individual product specifications.

The platform brings together catalogue navigation, research reading and available documentation without changing the products’ stated purpose. Educational material does not establish suitability for human use or replace the assessments required for a laboratory’s own work.

Maylene invites laboratory buyers to explore its featured range, compare available formats and review the relevant product information before ordering.

About Maylene

Maylene supplies research-use products dispatched from the United Kingdom. Its online catalogue includes individual compounds, prefilled research pens, blends and bundles, supported by educational resources and available laboratory documentation. The company offers free UK delivery and international shipping options.

Research-Use Notice

All products sold by Maylene are intended solely for laboratory and research purposes. They are not intended for human or veterinary use, consumption or application. Product descriptions and educational resources do not constitute medical advice.

Media Contact

Organization: Maylene

Contact Person: Sam Aquino

Website: https://www.maylene.uk/

Email: Send Email

Country: United Kingdom

Release id: 50483

View source version on King Newswire:
Maylene Showcases Its Best-Selling Research Peptides with UK-Wide Delivery

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST